In focus · trending topic

community-acquired pneumonia

2 stories · following the connections

BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week

By Nasdaq OMXOct 18, 2017, 5:34 PM UTC

BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia

By Nasdaq OMXOct 13, 2017, 2:00 PM UTC